People often tell Winona Williams that she’s brave, and she is. Ovarian cancer could easily become a dark cloud over her, shadowing every minute of every day.
Anschutz Cancer Pavilion
1665 North Aurora Court
Aurora, CO 80045
As genetic counseling and genetic testing continue gaining importance in the world of cancer, the new co-director of hereditary cancers in the University of Colorado Cancer Center is aiming to increase awareness of these important resources for patients.
PIK3CA is a gene that makes an enzyme called PI3K, which is involved in many important cell functions. When PIK3CA mutates, however, it can make the PI3K enzyme become overactive and cause cancer cells to grow.
An enzyme that has been identified as instrumental in the progression of many types of cancer is meeting its match in inhibitors synthesized and evaluated by University of Colorado (CU) Cancer Center researchers.
Paul Norman, PhD, was born in the Midlands region of Central England in the county town of Shrewsbury, which, coincidentally, is also the birthplace of the naturalist and explorer, Charles Darwin. And like Darwin, Norman set out on a mission to categorize the diversity of life. Only, while Darwin concerned himself with things he could see – the beak shape of Galapagos finches, for example – Norman explores the diversity of cells hidden inside our bodies. Even more specifically, Norman, who recently joined University of Colorado Cancer Center as a mentored member, researches the diversity of tiny proteins that sit on the surface cancer cells. What seems little could be very big: Differences in these proteins across ethnicities could help to explain the differences in cancer rates between human cultures.
During a roundtable event, Peter Forsberg, MD, discussed data from several trials of selinexor in patients with relapsed/refractory multiple myeloma.
November is Pancreatic Cancer Awareness Month. Laura Foote shares her story to bring hope and express gratitude.
Men are three to four times more likely than women to develop bladder cancer, but the disease tends to be deadlier in females. Why?
New therapeutic addresses need in patients suffering with cold and refractory tumors.